Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07516561
Starting soon Phase 3

Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

NCT07516561 · tracked via the Priya Life Science Brazil tracker
Sponsor
Apsen Farmaceutica S.A
Phase
Phase 3
Started
2026-10-07
Last updated
2026-09-08

Condition(s) studied

Alopecia, Androgenetic

Investigational drug(s) / intervention(s)

APSMNF 1APSMNF 2Eniagor®

APSMNF 1: Administer twice a day during 24 weeks.

APSMNF 2: Administer twice a day during 24 weeks.

Eniagor®: Administer twice a day during 24 weeks.

Study summary

The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.

Eligibility

Sex
MALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ; * Participants who use an acceptable contraceptive method, or who declare that their partner uses an acceptable contraceptive method, according to the protocol, and who agree to use it throughout the study period. Exclusion Criteria: * History of allergic reactions to any of the active ingredients or to any of the ingredients of teh formulation; * Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years; * Participants with conditions that may affect hair growth or with underlying conditions that cause hair loss, such as a diagnosis of alopecia areata, fibrosing or cicatricial alopecia, or telogen effluvium, the latter being present at the time of screening; * Participants with concomitant inflammation or other dermatological conditions of the scalp, such as moderate or severe psoriasis or seborrheic dermatitis, and/or active infection and/or keloid formation in the area of alopecia;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinica Geral Investiga Ltda Campinas São Paulo

More Apsen Farmaceutica S.A. trials in Brazil

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07516561 on ClinicalTrials.gov ↗ ← All trials in Brazil